Traditional serum biomarkers like PSA, though integral for screening and monitoring, suffer from low specificity (20–40%) due to elevation in benign conditions (e.g., BPH, prostatitis) [2,3,4,34]. Here, KLK3 is linked to benign prostatic hyperplasia.